Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID
APAL2020D
Disease (Sub Disease)
Acute myeloid leukemia
Diagnosis Stage
Relapsed/refractory
Location
QLD, WA, NZ
Sponsor
LLS PedAL Initiative, LLC
Collaborators
Princess Maxima Center for Pediatric Oncology (European Sponsor)
AbbVie
Roche-Genentech
EuPAL
AbbVie
Roche-Genentech
EuPAL
Links
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Starship Hospital
Queensland Children's Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
29 Days to 21 Years
International registry ID's
NCT05183035
| Study Title | A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML |
|---|---|
| Protocol ID | APAL2020D |
| Disease (Sub Disease) | Acute myeloid leukemia |
| Diagnosis Stage | Relapsed/refractory |
| Location | QLD / WA / NZ |
| Sponsor | LLS PedAL Initiative, LLC |
| Collaborators | Princess Maxima Center for Pediatric Oncology (European Sponsor)/ AbbVie/ Roche-Genentech/ EuPAL |
| Links | https://clinicaltrials.gov/ct2/show/NCT05183035 |
| Trial Status | Open |
| Trial Open Date | 01/10/2022 |
| Sites | Perth Children's Hospital/ Queensland Children's Hospital / Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 29 Days to 21 Years |
| International registry ID's | NCT05183035 |